News
KRYS
335.51
+0.97%
3.24
Weekly Report: what happened at KRYS last week (0810-0814)?
Weekly Report · 7h ago
Krystal Biotech initiated with an Outperform at RBC Capital
TipRanks · 1d ago
Micron upgraded, Cisco downgraded: Wall Street’s top analyst calls
TipRanks · 1d ago
Should Surging Vyjuvek-Driven Earnings Reshape How Krystal Biotech (KRYS) Investors View Its Risk Profile?
Simply Wall St · 1d ago
High-Profile Insider Trade Shakes Up Krystal Biotech
TipRanks · 2d ago
Krystal Bio granted bullish view at RBC after blockbuster projections
Seeking Alpha · 3d ago
Krystal Biotech Price Target Announced at $400.00/Share by RBC Capital
Dow Jones · 3d ago
Krystal Biotech Initiated at Outperform by RBC Capital
Dow Jones · 3d ago
RBC Capital Initiates Coverage On Krystal Biotech with Outperform Rating, Announces Price Target of $400
Benzinga · 3d ago
Krystal Biotech (KRYS) Has a New Rating from RBC Capital
TipRanks · 3d ago
Krystal Biotech (KRYS) Earnings And Pipeline Progress Put Valuation Back In Focus
Simply Wall St · 4d ago
Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS) and Immunic (IMUX)
TipRanks · 5d ago
Krystal Biotech (KRYS) Q2 2026 Earnings Call Transcript
The Motley Fool · 6d ago
Vertex Pharmaceuticals Inc. Stock Rises 5.6%, Outperforms Peers
Dow Jones · 6d ago
If You Invested $1000 In Krystal Biotech Stock 5 Years Ago, You Would Have This Much Today
Benzinga · 6d ago
Weekly Report: what happened at KRYS last week (0803-0807)?
Weekly Report · 08/10 10:12
SA Asks: What's the outlook for Big Pharma M&A?
Seeking Alpha · 08/08 19:28
Did Stronger Q2 2026 Profitability Just Shift Krystal Biotech's (KRYS) Investment Narrative?
Simply Wall St · 08/08 17:35
Krystal Biotech (KRYS) After Its Q2 Beat Is The Valuation Case Still Intact
Simply Wall St · 08/05 18:23
iShares Russell 2000 Growth ETF Experiences Big Outflow
NASDAQ · 08/05 14:49
More
Webull provides a variety of real-time KRYS stock news. You can receive the latest news about Krystal Biotech through multiple platforms. This information may help you make smarter investment decisions.
About KRYS
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.